Alnylam Pharmace. buy Subdi
Summary
This prediction ended on 06.09.18 with a price of €105.44. With a performance of -4.71%, the BUY prediction for Alnylam Pharmace. by Subdi closed slightly in the red. Subdi has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | -2.422% | -2.422% | 27.248% | 39.413% |
iShares Core DAX® | 1.560% | 4.721% | 18.671% | 17.397% |
iShares Nasdaq 100 | 0.517% | 1.171% | 23.619% | 35.896% |
iShares Nikkei 225® | 1.730% | 6.073% | 16.253% | 10.295% |
iShares S&P 500 | 1.482% | 1.218% | 23.290% | 38.843% |
Comments by Subdi for this prediction
In the thread Alnylam Pharmace. diskutieren
Subdi stimmt der Buy-Einschätzung von stratec zu
Subdi stimmt am 31.08.2018 der Buy-Einschätzung von stratec mit dem Kursziel 146,78$ zu.
Überschrift: Alnylam with its first new drug application and multiple clinical read-outs in 2018
Stopped prediction by Subdi for Alnylam Pharmace.
Alnylam Pharmace.
27.10.18
08.11.18
08.11.18
Alnylam Pharmace.
10.09.18
12.09.18
12.09.18